Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P33993
UPID:
MCM7_HUMAN
Alternative names:
CDC47 homolog; P1.1-MCM3
Alternative UPACC:
P33993; A4D2A1; A4D2A2; E9PGN9; Q15076; Q96D34; Q96GL1
Background:
DNA replication licensing factor MCM7, also known as CDC47 homolog and P1.1-MCM3, is a pivotal component of the MCM2-7 complex, the replicative helicase necessary for DNA replication initiation and elongation in eukaryotic cells. It forms a core part of the CDC45-MCM-GINS helicase, crucial for unwinding DNA during replication. The MCM7 protein, through its interaction with adjacent subunits, contributes to the formation of active ATPase sites essential for the helicase activity of the complex.
Therapeutic significance:
Understanding the role of DNA replication licensing factor MCM7 could open doors to potential therapeutic strategies.